Clinical trials: Influenza, completed
Healthy, Gastrointestinal Dysfunction
Efficacy of a Whole Cell Algae Fermentate on Gut Health and Overall Immune Function in Healthy Adults With Mild Gastrointestinal Issues
The objective of the current study is to evaluate the effect of whole cell fermentate on gut health, including GI system function, such as supporting consistency and regularity of bowel habits, as well as changes in microbiota.
- Conditions
- Healthy, Gastrointestinal Dysfunction, Cold Symptom, Flu Symptom
- Trial name
- NCT04735809
- Testing
- Whole Cell Algae Fermentate
- Where
- United States
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Kemin Foods LC
Influenza, Pandemic Influenza
Phase 1 Study of a H5N1 Influenza Vaccine (Reverse Genetic Reassortant)
The objectives of this study are to assess the dose-related safety and immunogenicity of six different dose levels of inactivated, Vero cell-derived reverse genetic reassortant A/H5N1/Indonesia/05/2005 influenza vaccine in a…
- Trial name
- NCT00783926
- Testing
- H5N1 Influenza Vaccine, Whole virion, Vero cell-derived, Inactivated Influenza Vaccine, non-adjuvanted (reverse genetic reassortant/H5N1 hemagglutinin antigen)
- Where
- 6 sites in United States
- Volunteers
- 422 people, healthy volunteers welcome
- Sponsor
- Alachua Government Services, Inc.
Influenza Vaccine
Safety and Immunogenicity of Cam2020 M2SR H3N2 Monovalent Influenza Vaccine Alone or With Licensed IIV in Older Adults
This is a randomized, double-blind, double-dummy, placebo-controlled Phase 1b study evaluating the safety and immunogenicity of the investigational Cam2020 M2SR H3N2 influenza vaccine delivered IN alone or concomitantly with…
- Trial name
- NCT05163847
- Testing
- Cam2020 M2SR H3N2 influenza vaccine, Fluzone HD IIV
- Where
- 6 sites in United States
- Volunteers
- 303 people, healthy volunteers welcome
- Sponsor
- FluGen Inc
Influenza
Study of the Influenza Vaccine (Split Virion, Inactivated) Northern Hemisphere 2009-2010 Formulation (Intradermal Route)
This study is in support of the annual application for the variation of the vaccine strains for a marketing authorisation. Objectives: To evaluate compliance, in terms of immunogenicity, of the corresponding strength of the…
- Trial name
- NCT00945438
- Testing
- Influenza virus vaccine 2009-2010 formulation
- Where
- 2 sites in France
- Volunteers
- 131 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Influenza Vaccine, Behavioral Intervention
Limits of the Social Benefit Motive Among High-risk Patients: a Field Experiment on Influenza Vaccination Behaviour
Influenza vaccine uptake remains low worldwide, inflicting substantial costs to public health and health systems. Messages promoting social welfare have been shown to increase vaccination intentions, and it has been recommended…
- Conditions
- Influenza Vaccine, Behavioral Intervention, Self-benefit, Social-benefit
- Trial name
- NCT04230343
- Testing
- Self-benefit message, Other-benefit message
- Where
- Turkey (Türkiye)
- Volunteers
- 244 people
- Sponsor
- SB Istanbul Education and Research Hospital
Seasonal Influenza, Cough
Safety Study of IV Peramivir in Hospitalized Subjects With Confirmed or Suspected Influenza
This is a Phase 3, open-label, randomized study of the antiviral activity, safety, and tolerability of intravenous Peramivir in hospitalized subjects with confirmed or suspected influenza infection.
- Conditions
- Seasonal Influenza, Cough, Sore Throat, Nasal Congestion
- Trial name
- NCT00957996
- Testing
- Peramivir
- Where
- 110 sites in United States, Australia and 4 more
- Volunteers
- 234 people
- Sponsor
- BioCryst Pharmaceuticals
Influenza
Higher Dose Intradermal H5 Vaccine
This study will compare the influenza A/H5N1 virus vaccine given by injection in the muscle versus injection in the skin in healthy adults.
- Trial name
- NCT00439335
- Testing
- Inactivated Influenza A Vaccine A/H5N1
- Where
- United States
- Volunteers
- 227 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Novel 2009 Influenza H1N1
Safety and Immunogenicity of A/H1N1-SOIV (Swine Flu) Vaccine With and Without Adjuvant in Children, Adolescents and Adults (3 to 64 Years)
This study will evaluate the safety and immunogenicity of different combinations of A/H1N1 S-OIV (swine flu) vaccine in healthy young children, adolescents, and adults.
- Trial name
- NCT00973700
- Testing
- MF59-eH1N1_f, eH1N1_f
- Where
- Costa Rica
- Volunteers
- 784 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Influenza
Study to Assess the Safety, Pharmacokinetics, and Efficacy of Baloxavir Marboxil in Healthy Pediatric Participants From Birth to < 1 Year With Influenza-Like Symptoms
This study will evaluate the safety, pharmacokinetics and efficacy of baloxavir marboxil in healthy pediatric participants from birth to <1 year with influenza like symptoms
- Trial name
- NCT03653364
- Testing
- Baloxavir Marboxil
- Where
- 27 sites in United States, Bulgaria and 7 more
- Volunteers
- 49 people
- Sponsor
- Hoffmann-La Roche
Seasonal Influenza
Safety and Immunogenicity of Influenza Vaccine (Surface Antigen, Inactivated) Ph.Eur, Formulation 2010/2011, When Administered to Adult and Elderly Subjects
Influenza poses a significant threat to individual and public health, and influenza vaccination with a trivalent inactivated influenza vaccine is widely recommended to children, adults at risks and elderly.
- Trial name
- NCT01161264
- Testing
- Influenza Vaccine (Surface Antigen, Inactivated) Ph.Eur, Formulation 2010/2011
- Where
- Germany
- Volunteers
- 126 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Childhood Influenza Vaccination, School-located Influenza Vaccination
School-located Influenza Vaccination Clinics for Adolescents
A cluster-randomized trial (clustering by school) was conducted in Monroe County, NY. Twenty middle and high schools were paired based on several characteristics and randomized within pairs to receiving a school-based influenza…
- Trial name
- SKIPP RCT2 (NCT03137667)
- Testing
- School-located Influenza Vaccination
- Volunteers
- 17,650 people
- Sponsor
- University of California, Los Angeles
Influenza
Safety and Immunogenicity of Three Influenza Vaccines in Children Aged 4 Years Old to Less Than 18 Years Old
Evaluate safety and immunogenicity of three influenza vaccines in children ages greater than 4 years old to less than 18 years old.
- Trial name
- NCT01992107
- Testing
- QIVc, TIV1c, TIV2c
- Where
- 88 sites in United States
- Volunteers
- 2,333 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Influenza
Adjuvanted Seasonal Recombinant Quadrivalent Virus-Like Particles (QVLP) Influenza Vaccine in Adults 65 Years of Age and Older
This randomized, partially-blinded, active comparator-controlled was conducted at multiple sites globally. The composition of QVLP used in this study includes a mix of recombinant H1, H3, and two B hemagglutinin proteins…
- Trial name
- NCT04622592
- Testing
- Instramuscular vaccine
- Where
- 14 sites in United States
- Volunteers
- 209 people, healthy volunteers welcome
- Sponsor
- Medicago
Influenza, Hepatitis A
Effects of Aging on Primary and Secondary Vaccine Responses
The purpose of this study is to use an existing, unique clinical cohort: the longitudinal cohort of younger (21-40 years) and elderly (>65 years) subjects whose yearly influenza vaccine responses have been studied extensively…
- Conditions
- Influenza, Hepatitis A, Typhoid, Healthy Adults
- Trial name
- SLVP033 (NCT03312699)
- Testing
- Fluzone® quadrivalent, Fluzone High Dose, Fluad
- Where
- United States
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Stanford University
Influenza
Assess the Risk of Solid Organ Transplant Rejection Following Vaccination With Pandemrix™ in UK
This study aims to assess the risk of solid organ transplant (SOT) rejection following vaccination with Pandemrix™ and/ or seasonal influenza vaccination.
- Trial name
- NCT01715792
- Testing
- Data collection
- Where
- United Kingdom
- Volunteers
- 587 people
- Sponsor
- GlaxoSmithKline
Seasonal Influenza
The Effect of a Planning Prompt on Seasonal Influenza Vaccination Rates
The investigators conducted a 3-arm randomized controlled trial to test whether a low-cost planning intervention could increase influence vaccination rates.
- Trial name
- NCT01207232
- Testing
- Planning Prompt, Control Condition
- Where
- United States
- Volunteers
- 3,272 people
- Sponsor
- University of Pennsylvania
Influenza, COVID-19
Natural History of Systemic and Nasal Mucosal Immunity to Influenza and SARS-CoV-2 in Adults After Vaccination
Background: Influenza (flu) vaccinations are required for all NIH staff members who have direct contact with patients. COVID-19 vaccines are recommended for persons 6 months of age and older.
- Trial name
- NCT04794829
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Influenza
Influenza Challenge Study in Healthy Volunteers
A study to determine the infectious titre of an Influenza A (H1N1) (A/New Caledonia/20/99) virus for use in other Influenza challenge studies for the development of Influenza vaccines, antiviral agents and to better understand…
- Trial name
- NCT02746211
- Testing
- High Titre Influenza virus, Medium - High Influenza virus, Medium Low Titre Influenza virus
- Where
- United Kingdom
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Hvivo
Virus Diseases, RNA Virus Infections
Efficacy, Safety, and Immunogenicity of a Plant-Derived Quadrivalent Virus-Like Particles (VLPs) Influenza Vaccine in Adults
This Phase 3 study is intended to assess the efficacy of the Quadrivalent VLP Influenza Vaccine during the 2017-2018 influenza season in healthy adults 18 to 64 years of age.
- Conditions
- Virus Diseases, RNA Virus Infections, Respiratory Tract Diseases, Respiratory Tract Infections
- Trial name
- NCT03301051
- Testing
- Quadrivalent VLP Vaccine
- Where
- 73 sites in United States, Canada and 5 more
- Volunteers
- 10,160 people, healthy volunteers welcome
- Sponsor
- Medicago
Avian Influenza, Influenza
H5N8 Mix and Match With or Without AS03 or MF59 in Healthy Adults
This is a Phase I randomized, double-blind, controlled trial in 275 males and non-pregnant females, 19 to 64 years old, inclusive, who are in good health and meet all eligibility criteria.
- Trial name
- NCT02624219
- Testing
- AS03, MF59 adjuvant, Monovalent Influenza A/H5N8 vaccine
- Where
- 4 sites in United States
- Volunteers
- 276 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.